Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 5/20 | 0.48 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.47 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PNMT | P11086 | 1/20 | 0.38 |
| ▸ | CD44 | P16070 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30474149 | 0.75 | HTR2C (0.48) | HTR2CMAOBPNMTCD44 | |
| SCHEMBL10313038 | 0.75 | HTR2C (0.48) | HTR2CGRM5CHRM4CHRM5CHRM1 | |
| SCHEMBL10313015 | 0.74 | HTR2C (0.42) | HTR2CMAOBPNMTCD44CHRM4 | |
| SCHEMBL23530210 | 0.74 | HTR2C (0.42) | HTR2CMAOBPNMTCD44HTR2A | |
| Hydrochloric Acid SCHEMBL30474224 | 0.74 | CHRM4 (0.47) | HTR2CGRM5CHRM4CHRM5CHRM1 | |
| SCHEMBL158402 | 0.71 | GRM5 (0.45) | GRM5MAPTCHRM4CHRM5CHRM1 | |
| SCHEMBL19033504 | 0.71 | HTR2C (0.41) | HTR2CMAOBPNMTCD44HTR2A | |
| SCHEMBL159293 | 0.69 | GRM5 (0.46) | GRM5MAPTCHRM4CHRM5CHRM1 | |
| SCHEMBL10313099 | 0.68 | GRM5 (0.49) | GRM5 | |
| SCHEMBL30199561 | 0.68 | SYK (0.56) | CD274MAOBMAOAPNMTCD44 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710074-B2 | Dihydronaphthyridinyl(organo)methanone analogs as positive allosteric mGluR5 modulators | VANDERBILT UNIVERSITY (US) | 2014-04-29 | — | — | US | disclosed |
| WO-2012097182-A1 | DIHYDRONAPHTHYRIDINYL(ORGANO)METHANONE ANALOGS AS POSITIVE ALLOSTERIC MGLUR5 MODULATORS | VANDERBILT UNIVERSITY (US) | 2012-07-19 | — | — | WO | disclosed |
| WO-2012097182-A1 | DIHYDRONAPHTHYRIDINYL(ORGANO)METHANONE ANALOGS AS POSITIVE ALLOSTERIC MGLUR5 MODULATORS | VANDERBILT UNIVERSITY (US) | 2012-07-19 | — | — | WO | disclosed |
| US-20120178776-A1 | DIHYDRONAPHTHYRIDINYL(ORGANO)METHANONE ANALOGS AS POSITIVE ALLOSTERIC MGLUR5 MODULATORS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-07-12 | — | — | US | disclosed |
| US-20120178776-A1 | DIHYDRONAPHTHYRIDINYL(ORGANO)METHANONE ANALOGS AS POSITIVE ALLOSTERIC MGLUR5 MODULATORS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178776-A1 | DIHYDRONAPHTHYRIDINYL(ORGANO)METHANONE ANALOGS AS POSITIVE ALLOSTERIC MGLUR5 MODULATORS | GRM5, GRIK5, GRM3 | KCNH2 905/4885HTR2C 91/4885CYSLTR2 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.